Category: Non classé

Biose Industrie begins its LBP manufacturing expansion into the US with new Boston office

Boston is one of the top global hubs for biotechnology companies developing live biotherapeutic products (LBPs), and many of these companies seek out the expertise of the world leading CDMO, France’s Biose Industrie. As of September, 2020, Biose Industrie’s manufacturing expertise will be even closer to these US organizations: the company has established a new office … Continue reading “Biose Industrie begins its LBP manufacturing expansion into the US with new Boston office”

Biose Industrie Initiaties Large-Scale Production of Biomica’s 4-Strain Candidate Consortium in its Immuno-Oncology Program

Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live Bacterial Product (LBP) candidate consortium. The microbes, which will be produced in large-scale are expected to support Biomica’s first-in-man proof-of-concept clinical trials for its immuno-oncology … Continue reading “Biose Industrie Initiaties Large-Scale Production of Biomica’s 4-Strain Candidate Consortium in its Immuno-Oncology Program”

Biose Industrie and strain characterisation – Growing and developing our service offering through strategic sponsoring of research projects

A company that supports the process development and manufacturing of live biotherapeutic products (LBPs) needs to know bacteria inside out: not just the potential therapeutic effects of the strains, but how the strains behave under different conditions and in different contexts. A better understanding of mechanisms of action, after all, allows better optimization of the … Continue reading “Biose Industrie and strain characterisation – Growing and developing our service offering through strategic sponsoring of research projects”

How Biose Industrie aims to extend its lead in LBP manufacturing with 30-million Euro investment

Live biotherapeutic products (LBPs), or live microorganisms employed as drugs, are relatively new on the pharmaceutical scene. Yet Biose Industrie CEO Adrien Nivoliez has his eye on the future. According to experts and market research, LBP development and manufacturing are set to grow exponentially as the field matures in the years ahead—and Nivoliez foresees that … Continue reading “How Biose Industrie aims to extend its lead in LBP manufacturing with 30-million Euro investment”

Biose Industrie raises EUR 30 million to strengthen its position as the reference CDMO in the field of microbiota

Aurillac, July 16, 2020 – Biose Industrie announced today the closing of a €30 million funding round led by Cathay Capital, alongside the company’s management team, banking partners and the Auvergne-Rhône-Alpes region. Thanks to this funding found, Biose Industrie will benefit from Cathay Capital’s support as it accelerates its development and strengthens its leadership position … Continue reading “Biose Industrie raises EUR 30 million to strengthen its position as the reference CDMO in the field of microbiota”

When drug manufacturers take on living medicines

Contract Development & Manufacturing Organizations (CDMOs) are critical partners for moving ahead with new drug products. But with a growing number of start-up companies working to develop microbiome-based products, are CDMOs ready to take on the challenges of manufacturing a whole new category of ‘living medicines’—live biotherapeutic products (LBPs)? Bharat Dixit, VP, Biopharmaceutical Development & Manufacturing at Morningside … Continue reading “When drug manufacturers take on living medicines”